logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • CD20-directed Cytolytic Antibody class drugs

    FiltersReset Filters
    7 results

    • briumvi

      (ublituximab)
      TG Therapeutics, Inc.
      Usage: BRIUMVI is indicated for the treatment of relapsing forms of multiple sclerosis (MS) in adults, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.

    • gazyva

      (obinutuzumab)
      Genentech, Inc.
      Usage: GAZYVA is indicated for the treatment of previously untreated chronic lymphocytic leukemia (CLL) in combination with chlorambucil. It is also indicated for follicular lymphoma (FL) in patients relapsed or refractory to rituximab, and for untreated stage II bulky, III, or IV FL in combination with chemotherapy.

    • kesimpta

      (ofatumumab)
      Novartis Pharmaceuticals Corporation
      Usage: KESIMPTA is indicated for treating relapsing forms of multiple sclerosis (MS) in adults, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.

    • ocrevus

      (ocrelizumab)
      Genentech, Inc.
      Usage: OCREVUS is indicated for the treatment of relapsing forms of multiple sclerosis (MS) in adults, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as for primary progressive MS in adults.

    • rituxan

      (rituximab)
      Genentech, Inc.
      Usage: RITUXAN is indicated for the treatment of various conditions including Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Rheumatoid Arthritis (RA), Granulomatosis with Polyangiitis (GPA), Microscopic Polyangiitis (MPA), and Pemphigus Vulgaris (PV) in adults and pediatric patients, as specified.

    • rituxan hycela

      (rituximab and hyaluronidase)
      Genentech, Inc.
      Usage: RITUXAN HYCELA is indicated for adults with relapsed/refractory follicular lymphoma, untreated follicular lymphoma with chemotherapy, non-progressing follicular lymphoma after initial CVP chemotherapy, untreated diffuse large B-cell lymphoma with CHOP, and chronic lymphocytic leukemia in combination with fludarabine and cyclophosphamide.

    • ruxience

      (rituximab-pvvr)
      Pfizer Laboratories Div Pfizer Inc
      Usage: RUXIENCE is indicated for adult patients with relapsed or refractory non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis (RA), and granulomatosis with polyangiitis and microscopic polyangiitis, often in combination with other therapies, depending on the specific condition and patient response.